<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681093</url>
  </required_header>
  <id_info>
    <org_study_id>CQAW039A2322</org_study_id>
    <secondary_id>2018-002073-22</secondary_id>
    <nct_id>NCT03681093</nct_id>
  </id_info>
  <brief_title>Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma</brief_title>
  <acronym>THUNDER</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Assessment of the Efficacy in Reduction of Nasal Polyp Size in Patients With Nasal Polyposis and Concomitant Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant dose 1 and dose 2,
      compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing
      endoscopic nasal polyp score in adult (≥ 18 years) patients with nasal polyposis and
      concomitant asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Actual">June 10, 2020</completion_date>
  <primary_completion_date type="Actual">May 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind, double dummy study design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal Polyp Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from baseline in Nasal Polyp Score (assessed by Nasal Endoscopy) following 16 weeks of treatment, compared to placebo. Total of 4 questions relating to nasal symptoms for the patients at the time the questionnaire is being administered. The questions score from 0 (not at all) to 3 (Severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms (Nasal Congestion Score)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from baseline in symptoms score (assessed by Nasal Congestion Score questionnaire) following 16 weeks of treatment, compared to placebo. One questions relating to nasal symptoms for the patients at the time the questionnaire is being administered. The question score from 0 (not at all) to 3 (Severe). Only one question (is your nose blocked?) will be used for this secondary objective so the result will be a score from 0 to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (SNOT-22)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from baseline in Quality of Life score (assessed using the SNOT-22 questionnaire) following 16 weeks of treatment, compared to placebo. A total of 22 questions relating to Sino-nasal quality of life and are asked relating to the previous 2 weeks. Each question has 6 possible answers ranging from 0 (No Problem) to 5 (Problem as bad as it can be). The scores are added together giving a result out of 110 for the patient at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smell (Smell Identification Test)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from baseline in Smell score (assessed using the University of Pennsylvania Smell Identification Test) following 16 weeks of treatment, compared to placebo. This is a paper based kit consisting of 4 booklets with 10 questions each. Each question has a &quot;scratch and sniff&quot; panel which the site staff scratch off and the patient then has to smell this and identify the smell from 1 of the multiple choice responses. The result is a score out of 40 with the higher score indicating a better sense of smell.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Asthma</condition>
  <condition>Nasal Polyps</condition>
  <condition>Bronchial Diseases</condition>
  <condition>Lung Diseases</condition>
  <condition>Nose Diseases</condition>
  <condition>Respiratory Hypersensitivity</condition>
  <condition>Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>fevipiprant Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QAW039 Dose 1 once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fevipiprant Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QAW039 Dose 2 once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to QAW039 once daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fevipiprant Dose 1</intervention_name>
    <description>QAW039 Dose 1 once daily (one tablet of blinded QAW039 Dose 1 to be given together with one tablet of blinded placebo to QAW039 Dose 2)</description>
    <arm_group_label>fevipiprant Dose 1</arm_group_label>
    <other_name>QAW039 Dose 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fevipiprant Dose 2</intervention_name>
    <description>QAW039 Dose 2 once daily (one tablet of blinded QAW039 Dose 2 to be given together with one tablet of blinded placebo to QAW039 Dose 1)</description>
    <arm_group_label>fevipiprant Dose 2</arm_group_label>
    <other_name>QAW039 Dose 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 Dose 1 and one tablet blinded placebo to QAW039 Dose 2)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or more with a diagnosis of nasal polyps with Nasal polyp score
             &gt;= 4 with minimum score of 2 in each nostril.

          -  Concomitant diagnosis of asthma for a period of at least 6 months prior to screening.

          -  Patients on stable asthma treatment of at least inhaled corticosteroids (any dose)
             alone for at least 6 months prior to screening or ICS for 6 months prior to screening
             with any required, inhaled medication (LABA, LAMA) added at least 6 weeks prior to
             screening.

        Exclusion Criteria:

          -  Asthma exacerbation, within 6 weeks prior to screening, that required systemic
             corticosteroids, hospitalization or emergency room visit.

          -  Chronic/maintenance use of oral corticosteroids (OCS) defined as any continuous use of
             OCS for a period of 1 month or more, within 1 year of screening

          -  Use of biologics for asthma or any other indications, that has the potential to
             interfere/affect either asthma or nasal polyposis disease progression, within 6 months
             of screening.

          -  Use of medication for sino-nasal symptoms (antibiotics with or without OCS) within 30
             days of screening or during the run-in period.

          -  Use of tetracycline or macrolide antibiotics specifically, within 8 weeks of
             screening.

          -  History of nasal surgery modifying the structure of the nose such that assessment of
             the nasal polyp score is not possible.

          -  Patients with baseline ACQ-5≥1.5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425BEN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florida</city>
        <state>Buenos Aires</state>
        <zip>B1602DQD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DBS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erpent</city>
        <zip>5100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G 6C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <state>Czech Republic</state>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svitavy</city>
        <state>Czech Republic</state>
        <zip>568 25</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kladno</city>
        <zip>27259</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Enschede</city>
        <zip>7511 JH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strzelce Opolskie</city>
        <zip>47 100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zawadzkie</city>
        <zip>47-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Nasal Polyposis</keyword>
  <keyword>Nasal polyps score</keyword>
  <keyword>nasal endoscopy</keyword>
  <keyword>nasal congestion score</keyword>
  <keyword>quality of life</keyword>
  <keyword>smell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Bronchial Diseases</mesh_term>
    <mesh_term>Respiratory Hypersensitivity</mesh_term>
    <mesh_term>Nose Diseases</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indoleacetic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

